Table 1 Patients’ demographics, baseline treatment, optimal stimulation parameters and number of recording sessions
From: Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder
Pts. | Group | Age | Gender | Duration of disease (years) | Baseline medications (dose) | Baseline UPDRS III motor score (PD) | Baseline Y-BOCS score (OCD) | Electrode location [x, y, z] | Optimal stimulation parameters left/right: (Frequency (Hz); pulse duration (μs); contact configuration; voltage (V)) | Number of recording sessions |
|---|---|---|---|---|---|---|---|---|---|---|
Jur 01 | PD | 66 | F | 8 | Stalevo 50 mg q4d Rasagiline 2 mg qid | 35 | – | Left: (−12, −4, −4.5) Right: (12.25, −3.5, −5.5) | Left: (180; 60; c + 9−; 2) Right: (180; 60; c + 1−; 1.9) | 15 |
Jur 02 | OCD | 50 | F | 35 | Clomipramine 75 mg bid Olanzapine 5 mg bid | – | 34 | Left: (−10.65, −1.5, −5) Right: (10.5, −1, −5.5) | Left: (130; 60; c + 9−; 1) Right: (130; 60; c + 1−; 1) | 39 |
Jur 03 | PD | 54 | M | 9 | Carbidopa 12.5 mg q3h Levodopa 125 mg q3h Biperiden 1 mg q4h Ropinirole 4 mg qid | 31 | – | Left: (−11.25, −1.75, −4.5) Right: (11, −2.5, −5) | Left: (130; 60; c + 9−; 2.1) Right: (130; 60; c + 1−; 1.6) | 15 |
Jur 04 | OCD | 34 | M | 20 | – | – | 36 | Left: (−11.25, −2.4, −5.25) Right: (11.25, −4, −4) | Left: (120; 60; c + 8−; 0.5) Right: (120; 60; c + 0−; 0.5) | 7a |
Jur 05 | PD | 52 | F | 10 | Carbidopa 25 mg q6h Levodopa 250 mg q6h | 42 | – | Left: (−10.5, −2.5, −4) Right: (10.75, −3.5, −5) | Left: (130; 60; c + 8–11−; 1.9) Right: (130; 60; c + 1–2−; 1.3) | 22 |
Jur 06 | PD | 52 | F | 9 | Carbidopa 25 mg q5h Levodopa 250 mg q5h Rasagiline 1 mg qid Ropinirole 8 mg qid | 43 | – | Left: (−11, −3, −4) Right: (11.5, −3, −4.5) | Left: (130; 60; c + 9–11−; 2.2) Right: (130; 60; c + 1–3−; 1.8) | 17 |
